Clinical Briefings™: Examining the Role of CGRPs for the Treatment of Cluster Headaches

Released On
March 27, 2020

Expires On
March 27, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Emergency Medicine, Neurology, Pain Management, Primary Care

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.0 Contact Hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, primary care physicians, nurse practitioners (NPs), physician assistants (PAs), nurses and other health care professionals who would be involved in the diagnosis and management of headache disorders.

Program Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on disease burden, the role of calcitonin gene-related peptide (CGRP) pathway, and clinical trial data of emerging therapies for cluster headache. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify unmet patient needs and the burden of cluster headache
  • Review the role of the CGRP pathway in the pathophysiology of cluster headache
  • Evaluate the safety and efficacy data from clinical trials of new and emerging therapies in treatment of patients with cluster headaches

Faculty

Stephen D. Silberstein, MD, FAHS, FAAN, FACP

Stephen D. Silberstein, MD, FAHS, FAAN, FACP

Director
Professor of Neurology
Jefferson Headache Center
Philadelphia, PA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Disclosures of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Faculty Disclosures:

Stephen D. Silberstein, MD, FAHS, FAAN, FACP

  • Consultant/ Advisory Panel Member: Abide Therapeutics; Alder BioPharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; CEFALY Technology; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Healthcare Holdings, LLC.; eNeura Inc.; electroCore, Inc; Impel NeuroPharma, Inc.; Eli Lilly and Company; Medscape, LLC; Novartis, Inc.; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; Trigemina, Inc.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Audio” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.